Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 26 March 2026Incoming appointee
4 itemsScheduled Appointment Date24 June 2026 (subject to election and appointment at the 150th Annual General Meeting of Shareholders and a subsequent Board of Directors meeting)
Julie Kim
Previous positionIncoming CEO
New positionRepresentative Director, President and CEO
Bruce Broussard
Previous positionInterim CEO of HP
New positionOutside Director, Audit and Supervisory Committee Member
Kimura Koichiro (木村 浩一郎)
Previous positionSenior Advisor, Eurasia Group
New positionOutside Director, Audit and Supervisory Committee Member
Paul Stoffels
Previous positionAdvisor, Galapagos (former CEO and Chair of the Board)
New positionOutside Directors
Date of birth6 June 1970 (Julie Kim only; Not disclosed for the others)
Year joined the company2019 (Julie Kim; Not disclosed for the others)
Number of shares held173,773 ADS (as of the date of this report; no common shares of the Company are held)
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Departing officer
7 itemsDate of departure24 June 2026
Christophe WeberStepping down
Former PositionRepresentative Director, President and CEO
Jean-Luc ButelStepping down
Former PositionOutside Directors
Ian ClarkStepping down
Former PositionOutside Directors
Fujimori Yoshiaki (藤森 義明)Stepping down
Former PositionOutside Directors
Hatsukawa Koji (初川 浩司)Stepping down
Former PositionOutside Directors
Higashi Emiko (東 恵美子)Stepping down
Former PositionOutside Directors
Michel OrsingerStepping down
Former PositionOutside Directors
New positionRetirement
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.Reason for departure
The Company has expressed its gratitude for their tremendous efforts and immeasurable contributions to Takeda over approximately the past 10 years, but individual reasons for retirement are Not disclosed
Whether the incumbent will remain in office (whether they will retain their position)
Scheduled to retire from the Board of Directors (Christophe Weber). The other 6 individuals are also scheduled to retire as outside directors
Directors after the change11Number
Shareholders’ meeting approvalRequired. Director candidates are scheduled to be proposed at the 150th Annual General Meeting of Shareholders (24 June 2026)
Reason for change
To strengthen the Board of Directors’ oversight and advisory functions, ensure a smooth CEO transition, and support disciplined business operations aimed at long-term growth
Reasons for appointment
Bruce Broussard, Kimura Koichiro (木村 浩一郎) and Paul Stoffels are expected to contribute to strengthening the Board of Directors’ oversight and advisory functions through their extensive management experience, international business management experience, and expertise in healthcare and healthcare technology, geopolitics, corporate governance, and pharmaceutical research and development
| Item | Details |
|---|---|
| Resolution date | 26 March 2026 |
| Scheduled Appointment Date | 24 June 2026 (subject to election and appointment at the 150th Annual General Meeting of Shareholders and a subsequent Board of Directors meeting) |
| Date of departure | 24 June 2026 |
| Name of appointee | Julie Kim, Bruce Broussard, Kimura Koichiro (木村 浩一郎), Paul Stoffels |
| Appointee's new position | Representative Director, President and CEO, Outside Director, Audit and Supervisory Committee Member, Outside Director, Audit and Supervisory Committee Member, Outside Directors |
| Appointee's previous position | Incoming CEO, Interim CEO of HP, Senior Advisor, Eurasia Group, Advisor, Galapagos (former CEO and Chair of the Board) |
| Appointee's date of birth | 6 June 1970 (Julie Kim only; Not disclosed for the others) |
| Year the appointee joined the Company | 2019 (Julie Kim; Not disclosed for the others) |
| Number of shares held by the appointee | 173,773 ADS (as of the date of this report; no common shares of the Company are held) |
| Name of departing officer | Christophe Weber, Jean-Luc Butel, Ian Clark, Fujimori Yoshiaki (藤森 義明), Hatsukawa Koji (初川 浩司), Higashi Emiko (東 恵美子), Michel Orsinger |
| Former position of departing officer | Representative Director, President and CEO, Outside Directors, Outside Directors, Outside Directors, Outside Directors, Outside Directors, Outside Directors |
| New position of departing officer | Retirement |
| Reason for departure | The Company has expressed its gratitude for their tremendous efforts and immeasurable contributions to Takeda over approximately the past 10 years, but individual reasons for retirement are Not disclosed |
| Whether the incumbent will remain in office | Scheduled to retire from the Board of Directors (Christophe Weber). The other 6 individuals are also scheduled to retire as outside directors |
| Reason for change | To strengthen the Board of Directors’ oversight and advisory functions, ensure a smooth CEO transition, and support disciplined business operations aimed at long-term growth |
| Reasons for appointment | Bruce Broussard, Kimura Koichiro (木村 浩一郎) and Paul Stoffels are expected to contribute to strengthening the Board of Directors’ oversight and advisory functions through their extensive management experience, international business management experience, and expertise in healthcare and healthcare technology, geopolitics, corporate governance, and pharmaceutical research and development |
| Number of directors after the change | 11 directors (8 directors who are not Audit and Supervisory Committee Members and 3 directors who are Audit and Supervisory Committee Members). 9 outside directors |
| Subject to Approval by the General Meeting of Shareholders | Required. Director candidates are scheduled to be proposed at the 150th Annual General Meeting of Shareholders (24 June 2026) |
Items this document does not state (3)
Filing as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the Board of Directors’ oversight and advisory functions, ensure a smooth CEO transition, and support disciplined business operations aimed at long-term growth. The 6 retiring outside directors have been thanked for their contributions over approximately the past 10 years.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.